CalciMedica (NASDAQ:CALC) Given “Buy” Rating at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of CalciMedica (NASDAQ:CALC) in a report released on Tuesday morning, Benzinga reports. They currently have a $20.00 target price on the stock.

Several other analysts also recently weighed in on the stock. Singular Research raised shares of CalciMedica to a moderate buy rating in a research report on Friday, June 28th. Oppenheimer reissued an outperform rating and set a $14.00 target price on shares of CalciMedica in a research report on Monday, April 1st.

CalciMedica Stock Up 3.6 %

Shares of CalciMedica stock opened at $4.89 on Tuesday. The company has a market cap of $52.57 million, a P/E ratio of -2.27 and a beta of 1.28. CalciMedica has a 52-week low of $1.75 and a 52-week high of $8.38. The firm’s 50 day moving average price is $5.06 and its 200-day moving average price is $4.69.

CalciMedica (NASDAQ:CALC) last released its earnings results on Monday, May 13th. The company reported ($0.43) earnings per share for the quarter, topping the consensus estimate of ($0.50) by $0.07. As a group, equities research analysts forecast that CalciMedica will post -2.15 EPS for the current fiscal year.

Insider Buying and Selling at CalciMedica

In other CalciMedica news, Director Robert N. Wilson acquired 8,443 shares of the firm’s stock in a transaction on Thursday, June 27th. The stock was acquired at an average cost of $3.23 per share, for a total transaction of $27,270.89. Following the purchase, the director now owns 258,918 shares in the company, valued at approximately $836,305.14. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Company insiders own 53.30% of the company’s stock.

Hedge Funds Weigh In On CalciMedica

Several large investors have recently made changes to their positions in the company. Hudson Bay Capital Management LP acquired a new position in shares of CalciMedica in the 3rd quarter valued at $432,000. BML Capital Management LLC lifted its stake in shares of CalciMedica by 10.3% in the 1st quarter. BML Capital Management LLC now owns 160,424 shares of the company’s stock valued at $667,000 after purchasing an additional 15,000 shares during the period. Finally, Meritage Portfolio Management lifted its stake in shares of CalciMedica by 360.0% in the 4th quarter. Meritage Portfolio Management now owns 46,000 shares of the company’s stock valued at $132,000 after purchasing an additional 36,000 shares during the period.

CalciMedica Company Profile

CalciMedica, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia.